Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 20:51 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

ClinicalTrials.gov · NCT00589472 · Registry updated: 2017-10-06

Condition / research focus: Prostate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
Sponsor: National Cancer Institute (NCI)
Countries with listed sites: United States
Registry dates and results: Start: 2007-11. Completion: 2010-06 (may be estimated). Results are posted in this registry.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bicalutamide (drug) — also listed as: Casodex, Cosudex, ICI 176,334, ICI 176334
Goserelin Acetate (drug) — also listed as: ZDX, Zoladex
Laboratory Biomarker Analysis (other)
Leuprolide Acetate (drug) — also listed as: A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur
Therapeutic Conventional Surgery (procedure)
Vorinostat (drug) — also listed as: L-001079038, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza

Where the study takes place — 15 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Site recruitment: Not reported
UCSF Medical Center-Parnassus
San Francisco, California, United States
Site recruitment: Not reported
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Site recruitment: Not reported
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Site recruitment: Not reported
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Site recruitment: Not reported
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Site recruitment: Not reported
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
Site recruitment: Not reported
Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported
UMDNJ - New Jersey Medical School
Newark, New Jersey, United States
Site recruitment: Not reported
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported
Duke University Medical Center
Durham, North Carolina, United States
Site recruitment: Not reported
Oregon Health and Science University
Portland, Oregon, United States
Site recruitment: Not reported
M D Anderson Cancer Center
Houston, Texas, United States
Site recruitment: Not reported
University of Washington Medical Center
Seattle, Washington, United States
Site recruitment: Not reported
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control

ClinicalTrials.gov · NCT02920359 · Registry updated: 2017-10-06

Condition / research focus: There Are no Conditions Under Study. Healthy Volunteers
Sponsor: Parc de Salut Mar
Countries with listed sites: No country reported
Registry dates and results: Start: 2016-11-17. Completion: 2017-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LEUPRORELIN ACETATE (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer

ClinicalTrials.gov · NCT02911350 · Registry updated: 2017-10-02

Condition / research focus: Prostate Cancer
Sponsor: NYU Langone Health
Countries with listed sites: No country reported
Registry dates and results: Start: 2000-05. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Hormone Suppressors (drug)
Paclitaxel (drug) — also listed as: Abraxane
Radiation Therapy (radiation)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol

ClinicalTrials.gov · NCT03263299 · Registry updated: 2017-08-28

Condition / research focus: Invitro Fertilization
Sponsor: Cairo University
Countries with listed sites: Egypt
Registry dates and results: Start: 2017-08. Completion: 2018-09 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

cabergoline (drug)
Aspirin (drug)
GnRH agonist (drug)

Where the study takes place — 1 listed sites

Kasr Alainy medical school
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

CKD-841 Pharmacokinetic/Pharmacodynamic Study

ClinicalTrials.gov · NCT03233932 · Registry updated: 2017-07-31

Condition / research focus: Postmenopausal Disorder
Sponsor: Chong Kun Dang Pharmaceutical
Countries with listed sites: South Korea
Registry dates and results: Start: 2016-04. Completion: 2017-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LeuplinⓡInj (drug)
CKD-841 (drug)

Where the study takes place — 1 listed sites

Severance Hospital
Seoul, Yonsei-ro, Seodaemun-gu 50-1, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone

ClinicalTrials.gov · NCT03211052 · Registry updated: 2017-07-07

Condition / research focus: Prostate Cancer
Sponsor: Centre of Experimental Medicine
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2013-02-18. Completion: 2015-06-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TAK-700 and LHRH agonist (drug) — also listed as: Orteronel (TAK 700), LHRH-Leuprorelin Acetate
prostatectomy (procedure)

Where the study takes place — 1 listed sites

St Bartholomew's Hospital
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4WithdrawnINTERVENTIONAL

Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy

ClinicalTrials.gov · NCT00507780 · Registry updated: 2017-07-02

Condition / research focus: Ovarian Function; Preservation of Ovarian Function
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Countries with listed sites: United States
Registry dates and results: Start: 2007-07-18. Completion: 2010-07-22 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH antagonist (drug)

Where the study takes place — 1 listed sites

National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

ClinicalTrials.gov · NCT01257802 · Registry updated: 2017-06-27

Condition / research focus: Lupus Erythematosus, Systemic; Systemic Vasculitis; Isolated Angiitis of Central Nervous System; Lung Disease With Systemic Sclerosis; Lung Disease Interstitial Diffuse
Sponsor: Joseph Mccune
Countries with listed sites: United States
Registry dates and results: Start: 2011-05. Completion: 2015-11 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

depot leuprolide acetate 3.75 mg (drug) — also listed as: LUPRON depot 3.75 mg
Placebo (drug)

Where the study takes place — 2 listed sites

University of Michigan
Ann Arbor, Michigan, United States
Site recruitment: Not reported
The Ohio State University
Columbus, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

ClinicalTrials.gov · NCT01023061 · Registry updated: 2017-06-06

Condition / research focus: Adenocarcinoma of the Prostate; Stage II Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Sponsor: University of Washington
Countries with listed sites: United States
Registry dates and results: Start: 2010-03. Completion: 2015-09 (may be estimated). Results are posted in this registry.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

abiraterone acetate (drug) — also listed as: Zytiga
prednisone (drug) — also listed as: DeCortin, Deltra
leuprolide acetate (drug) — also listed as: Enantone, Lupron, Lupron Depot
laboratory biomarker analysis (other)
external beam radiation therapy (radiation)
goserelin acetate (drug) — also listed as: Zoladex

Where the study takes place — 2 listed sites

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
Site recruitment: Not reported
MultiCare Regional Cancer Center - Tacoma
Tacoma, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer

ClinicalTrials.gov · NCT00225420 · Registry updated: 2017-06-01

Condition / research focus: Prostate Cancer
Sponsor: UNC Lineberger Comprehensive Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2005-08. Completion: 2012-08 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

docetaxel (drug) — also listed as: Taxotere
leuprolide acetate (drug) — also listed as: Lupron, Eligard, Viadur, Zoladex
radiation therapy (radiation)

Where the study takes place — 2 listed sites

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States
Site recruitment: Not reported
Rex Cancer Center at Rex Hospital
Raleigh, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

ClinicalTrials.gov · NCT01431391 · Registry updated: 2017-05-30

Condition / research focus: Prostatic Neoplasm; Prostate Cancer; Prostatic Adenocarcinoma
Sponsor: Dendreon
Countries with listed sites: United States
Registry dates and results: Start: 2011-09. Completion: 2014-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

sipuleucel-T (biological) — also listed as: PROVENGE®, APC8015
leuprolide acetate (drug) — also listed as: Eligard®

Where the study takes place — 14 listed sites

Urology Center of Alabama
Homewood, Alabama, United States
Site recruitment: Not reported
University of California San Diego / Moores Cancer Center
La Jolla, California, United States
Site recruitment: Not reported
Keck Hospital of USC
Los Angeles, California, United States
Site recruitment: Not reported
LAC + USC Medical Center
Los Angeles, California, United States
Site recruitment: Not reported
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Site recruitment: Not reported
The Urology Center of Colorado
Denver, Colorado, United States
Site recruitment: Not reported
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
Site recruitment: Not reported
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Site recruitment: Not reported
NYOH Albany Cancer Center at Patroon Creek
Albany, New York, United States
Site recruitment: Not reported
Community Care Physicians, PC
Albany, New York, United States
Site recruitment: Not reported
Grand Strand Urology
Myrtle Beach, South Carolina, United States
Site recruitment: Not reported
Urology San Antonio Research
San Antonio, Texas, United States
Site recruitment: Not reported
Virginia Mason Medical Center
Seattle, Washington, United States
Site recruitment: Not reported
Seattle Cancer Care Alliance
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1TerminatedINTERVENTIONAL

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

ClinicalTrials.gov · NCT01642732 · Registry updated: 2017-05-30

Condition / research focus: Prostate Cancer
Sponsor: University of Michigan Rogel Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2012-10. Completion: 2014-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Everolimus, lupron, bicalutamide, and radiation (other) — also listed as: afinitor, RAD-001, Casodex, Leuprolide, Eligard

Where the study takes place — 2 listed sites

Georgetown University
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

ClinicalTrials.gov · NCT00658697 · Registry updated: 2017-05-25

Condition / research focus: Prostate Cancer
Sponsor: Dana-Farber Cancer Institute
Countries with listed sites: United States
Registry dates and results: Start: 2008-06. Completion: 2015-06 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Docetaxel (drug) — also listed as: Taxotere, Docecad
Bevacizumab (drug) — also listed as: Avastin
ADT (drug) — also listed as: Lupron or Zoladex
Bicalutamide (drug) — also listed as: Casodex, Cosudex, Calutide, Kalumid

Where the study takes place — 3 listed sites

University of Maryland - Greenebaum Cancer Center
Baltimore, Maryland, United States
Site recruitment: Not reported
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Site recruitment: Not reported
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer

ClinicalTrials.gov · NCT02107391 · Registry updated: 2017-05-24

Condition / research focus: Prostate Cancer
Sponsor: SOTIO a.s.
Countries with listed sites: Czechia
Registry dates and results: Start: 2012-03. Completion: 2016-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dendritic Cells DCVAC/PCa (biological)
Leuprolide acetate (drug) — also listed as: Lupron
Goserelin Acetate (drug) — also listed as: Zoladex

Where the study takes place — 9 listed sites

Facility not reported
Jablonec nad Nisou, Czechia
Site recruitment: Not reported
Facility not reported
Jihlava, Czechia
Site recruitment: Not reported
Facility not reported
Liberec, Czechia
Site recruitment: Not reported
Facility not reported
Mníšek pod Brdy, Czechia
Site recruitment: Not reported
Facility not reported
Olomouc, Czechia
Site recruitment: Not reported
Facility not reported
Pilsen, Czechia
Site recruitment: Not reported
Facility not reported
Prague, Czechia
Site recruitment: Not reported
Facility not reported
Ústí nad Labem, Czechia
Site recruitment: Not reported
Facility not reported
Zlín, Czechia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

ClinicalTrials.gov · NCT00170157 · Registry updated: 2017-05-15

Condition / research focus: Prostate Adenocarcinoma; Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage III Prostate Cancer; Stage IV Prostate Cancer
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2004-06. Completion: 2013-06 (may be estimated). Results are posted in this registry.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bicalutamide (drug) — also listed as: Casodex, Cosudex, ICI 176,334, ICI 176334
Flutamide (drug) — also listed as: 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Chimax, Drogenil, Euflex, Eulexin, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolid, Oncosal, Profamid, Prostacur, Prostadirex, Prostica, Prostogenat, SCH 13521, Tafenil, Tecnoflut, Testotard
Goserelin Acetate (drug) — also listed as: ZDX, Zoladex
Ipilimumab (drug) — also listed as: Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy
Leuprolide Acetate (drug) — also listed as: A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur
Pharmacological Study (other)

Where the study takes place — 1 listed sites

Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer

ClinicalTrials.gov · NCT02212197 · Registry updated: 2017-04-25

Condition / research focus: Prostate Cancer
Sponsor: Camurus AB
Countries with listed sites: Finland · Hungary
Registry dates and results: Start: 2014-09. Completion: 2016-03 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

leuprolide acetate FluidCrystal® injection depot (drug) — also listed as: CAM2032
leuprolide acetate (drug) — also listed as: Eligard

Where the study takes place — 7 listed sites

Docrates Cancer Center
Helsinki, Finland
Site recruitment: Not reported
University Hospital of Helsinki, Department of Urology
Helsinki, Finland
Site recruitment: Not reported
Tampere University Hospital, Department of Urology
Tampere, Finland
Site recruitment: Not reported
University Hospital of Turku, Department of Urology
Turku, Finland
Site recruitment: Not reported
Semmelweis University Hospital Department of Urology
Budapest, Hungary
Site recruitment: Not reported
Szent Imre Teaching Hospital
Budapest, Hungary
Site recruitment: Not reported
University of Debrecen, Medical Health Sciences Center, Department of Urology
Debrecen, Hungary
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial

ClinicalTrials.gov · NCT00380406 · Registry updated: 2017-04-05

Condition / research focus: Fertility Preservation; Cancer
Sponsor: Ottawa Hospital Research Institute
Countries with listed sites: Canada
Registry dates and results: Start: 2007-01. Completion: 2010-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprolide acetate (drug)

Where the study takes place — 4 listed sites

Cancer Centre of Southeastern Ontario
Kingston, Ontario, Canada
Site recruitment: Not reported
Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, Canada
Site recruitment: Not reported
Kingston General Hospital
Ottawa, Ontario, Canada
Site recruitment: Not reported
Ottawa Hospital/OHRI
Ottawa, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"

ClinicalTrials.gov · NCT02167893 · Registry updated: 2017-03-29

Condition / research focus: Prostate Cancer
Sponsor: Takeda
Countries with listed sites: No country reported
Registry dates and results: Start: 2005-10. Completion: 2010-12 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprorelin acetate (drug) — also listed as: Leuplin SR 11.25 mg Injection Kit

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Relationship Between the Menstrual Cycle and Heart Disease in Women

ClinicalTrials.gov · NCT01546454 · Registry updated: 2017-03-22

Condition / research focus: Coronary Heart Disease
Sponsor: Oregon Health and Science University
Countries with listed sites: United States
Registry dates and results: Start: 2012-02. Completion: 2013-01 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ethinyl Estradiol-Levonorgestrel combination (drug) — also listed as: Portia 21, Portia 28
leuprolide acetate (drug) — also listed as: Eligard
Estradiol (drug) — also listed as: Vivelle-Dot
Progesterone (drug) — also listed as: First-Progesterone VGS

Where the study takes place — 1 listed sites

Oregon Health & Sciences University, Department of Obstetrics and Gynecology, Women's Health Research Unit
Portland, Oregon, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease

ClinicalTrials.gov · NCT01933022 · Registry updated: 2017-03-09

Condition / research focus: Metastatic Prostate Cancer
Sponsor: Astellas Pharma Europe Ltd.
Countries with listed sites: Netherlands
Registry dates and results: Start: 2014-08. Completion: 2015-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Eligard (drug) — also listed as: Leuprorelin acetate

Where the study takes place — 3 listed sites

Site NL31005 St. Antonius ziekenhuis
Nieuwegein, Netherlands
Site recruitment: Not reported
Site NL31004 Radboudumc
Nijmegen, Netherlands
Site recruitment: Not reported
Site NL31001 Canisius-Wilhelmina Ziekenhuis
Nijmegen, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 20:51 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

ClinicalTrials.gov · NCT00589472 · Registry updated: 2017-10-06

Condition / research focus: Prostate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
Sponsor: National Cancer Institute (NCI)
Countries with listed sites: United States
Registry dates and results: Start: 2007-11. Completion: 2010-06 (may be estimated). Results are posted in this registry.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bicalutamide (drug) — also listed as: Casodex, Cosudex, ICI 176,334, ICI 176334
Goserelin Acetate (drug) — also listed as: ZDX, Zoladex
Laboratory Biomarker Analysis (other)
Leuprolide Acetate (drug) — also listed as: A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur
Therapeutic Conventional Surgery (procedure)
Vorinostat (drug) — also listed as: L-001079038, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza

Where the study takes place — 15 listed sites

UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Site recruitment: Not reported
UCSF Medical Center-Parnassus
San Francisco, California, United States
Site recruitment: Not reported
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Site recruitment: Not reported
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Site recruitment: Not reported
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Site recruitment: Not reported
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Site recruitment: Not reported
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
Site recruitment: Not reported
Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported
UMDNJ - New Jersey Medical School
Newark, New Jersey, United States
Site recruitment: Not reported
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported
Duke University Medical Center
Durham, North Carolina, United States
Site recruitment: Not reported
Oregon Health and Science University
Portland, Oregon, United States
Site recruitment: Not reported
M D Anderson Cancer Center
Houston, Texas, United States
Site recruitment: Not reported
University of Washington Medical Center
Seattle, Washington, United States
Site recruitment: Not reported
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control

ClinicalTrials.gov · NCT02920359 · Registry updated: 2017-10-06

Condition / research focus: There Are no Conditions Under Study. Healthy Volunteers
Sponsor: Parc de Salut Mar
Countries with listed sites: No country reported
Registry dates and results: Start: 2016-11-17. Completion: 2017-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LEUPRORELIN ACETATE (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer

ClinicalTrials.gov · NCT02911350 · Registry updated: 2017-10-02

Condition / research focus: Prostate Cancer
Sponsor: NYU Langone Health
Countries with listed sites: No country reported
Registry dates and results: Start: 2000-05. Completion: 2016-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Hormone Suppressors (drug)
Paclitaxel (drug) — also listed as: Abraxane
Radiation Therapy (radiation)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol

ClinicalTrials.gov · NCT03263299 · Registry updated: 2017-08-28

Condition / research focus: Invitro Fertilization
Sponsor: Cairo University
Countries with listed sites: Egypt
Registry dates and results: Start: 2017-08. Completion: 2018-09 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

cabergoline (drug)
Aspirin (drug)
GnRH agonist (drug)

Where the study takes place — 1 listed sites

Kasr Alainy medical school
Cairo, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

CKD-841 Pharmacokinetic/Pharmacodynamic Study

ClinicalTrials.gov · NCT03233932 · Registry updated: 2017-07-31

Condition / research focus: Postmenopausal Disorder
Sponsor: Chong Kun Dang Pharmaceutical
Countries with listed sites: South Korea
Registry dates and results: Start: 2016-04. Completion: 2017-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LeuplinⓡInj (drug)
CKD-841 (drug)

Where the study takes place — 1 listed sites

Severance Hospital
Seoul, Yonsei-ro, Seodaemun-gu 50-1, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone

ClinicalTrials.gov · NCT03211052 · Registry updated: 2017-07-07

Condition / research focus: Prostate Cancer
Sponsor: Centre of Experimental Medicine
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2013-02-18. Completion: 2015-06-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TAK-700 and LHRH agonist (drug) — also listed as: Orteronel (TAK 700), LHRH-Leuprorelin Acetate
prostatectomy (procedure)

Where the study takes place — 1 listed sites

St Bartholomew's Hospital
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4WithdrawnINTERVENTIONAL

Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy

ClinicalTrials.gov · NCT00507780 · Registry updated: 2017-07-02

Condition / research focus: Ovarian Function; Preservation of Ovarian Function
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Countries with listed sites: United States
Registry dates and results: Start: 2007-07-18. Completion: 2010-07-22 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH antagonist (drug)

Where the study takes place — 1 listed sites

National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

ClinicalTrials.gov · NCT01257802 · Registry updated: 2017-06-27

Condition / research focus: Lupus Erythematosus, Systemic; Systemic Vasculitis; Isolated Angiitis of Central Nervous System; Lung Disease With Systemic Sclerosis; Lung Disease Interstitial Diffuse
Sponsor: Joseph Mccune
Countries with listed sites: United States
Registry dates and results: Start: 2011-05. Completion: 2015-11 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

depot leuprolide acetate 3.75 mg (drug) — also listed as: LUPRON depot 3.75 mg
Placebo (drug)

Where the study takes place — 2 listed sites

University of Michigan
Ann Arbor, Michigan, United States
Site recruitment: Not reported
The Ohio State University
Columbus, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer

ClinicalTrials.gov · NCT01023061 · Registry updated: 2017-06-06

Condition / research focus: Adenocarcinoma of the Prostate; Stage II Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Sponsor: University of Washington
Countries with listed sites: United States
Registry dates and results: Start: 2010-03. Completion: 2015-09 (may be estimated). Results are posted in this registry.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

abiraterone acetate (drug) — also listed as: Zytiga
prednisone (drug) — also listed as: DeCortin, Deltra
leuprolide acetate (drug) — also listed as: Enantone, Lupron, Lupron Depot
laboratory biomarker analysis (other)
external beam radiation therapy (radiation)
goserelin acetate (drug) — also listed as: Zoladex

Where the study takes place — 2 listed sites

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
Site recruitment: Not reported
MultiCare Regional Cancer Center - Tacoma
Tacoma, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer

ClinicalTrials.gov · NCT00225420 · Registry updated: 2017-06-01

Condition / research focus: Prostate Cancer
Sponsor: UNC Lineberger Comprehensive Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2005-08. Completion: 2012-08 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

docetaxel (drug) — also listed as: Taxotere
leuprolide acetate (drug) — also listed as: Lupron, Eligard, Viadur, Zoladex
radiation therapy (radiation)

Where the study takes place — 2 listed sites

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States
Site recruitment: Not reported
Rex Cancer Center at Rex Hospital
Raleigh, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

ClinicalTrials.gov · NCT01431391 · Registry updated: 2017-05-30

Condition / research focus: Prostatic Neoplasm; Prostate Cancer; Prostatic Adenocarcinoma
Sponsor: Dendreon
Countries with listed sites: United States
Registry dates and results: Start: 2011-09. Completion: 2014-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

sipuleucel-T (biological) — also listed as: PROVENGE®, APC8015
leuprolide acetate (drug) — also listed as: Eligard®

Where the study takes place — 14 listed sites

Urology Center of Alabama
Homewood, Alabama, United States
Site recruitment: Not reported
University of California San Diego / Moores Cancer Center
La Jolla, California, United States
Site recruitment: Not reported
Keck Hospital of USC
Los Angeles, California, United States
Site recruitment: Not reported
LAC + USC Medical Center
Los Angeles, California, United States
Site recruitment: Not reported
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Site recruitment: Not reported
The Urology Center of Colorado
Denver, Colorado, United States
Site recruitment: Not reported
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
Site recruitment: Not reported
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Site recruitment: Not reported
NYOH Albany Cancer Center at Patroon Creek
Albany, New York, United States
Site recruitment: Not reported
Community Care Physicians, PC
Albany, New York, United States
Site recruitment: Not reported
Grand Strand Urology
Myrtle Beach, South Carolina, United States
Site recruitment: Not reported
Urology San Antonio Research
San Antonio, Texas, United States
Site recruitment: Not reported
Virginia Mason Medical Center
Seattle, Washington, United States
Site recruitment: Not reported
Seattle Cancer Care Alliance
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1TerminatedINTERVENTIONAL

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

ClinicalTrials.gov · NCT01642732 · Registry updated: 2017-05-30

Condition / research focus: Prostate Cancer
Sponsor: University of Michigan Rogel Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2012-10. Completion: 2014-08 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Everolimus, lupron, bicalutamide, and radiation (other) — also listed as: afinitor, RAD-001, Casodex, Leuprolide, Eligard

Where the study takes place — 2 listed sites

Georgetown University
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

ClinicalTrials.gov · NCT00658697 · Registry updated: 2017-05-25

Condition / research focus: Prostate Cancer
Sponsor: Dana-Farber Cancer Institute
Countries with listed sites: United States
Registry dates and results: Start: 2008-06. Completion: 2015-06 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Docetaxel (drug) — also listed as: Taxotere, Docecad
Bevacizumab (drug) — also listed as: Avastin
ADT (drug) — also listed as: Lupron or Zoladex
Bicalutamide (drug) — also listed as: Casodex, Cosudex, Calutide, Kalumid

Where the study takes place — 3 listed sites

University of Maryland - Greenebaum Cancer Center
Baltimore, Maryland, United States
Site recruitment: Not reported
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Site recruitment: Not reported
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer

ClinicalTrials.gov · NCT02107391 · Registry updated: 2017-05-24

Condition / research focus: Prostate Cancer
Sponsor: SOTIO a.s.
Countries with listed sites: Czechia
Registry dates and results: Start: 2012-03. Completion: 2016-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dendritic Cells DCVAC/PCa (biological)
Leuprolide acetate (drug) — also listed as: Lupron
Goserelin Acetate (drug) — also listed as: Zoladex

Where the study takes place — 9 listed sites

Facility not reported
Jablonec nad Nisou, Czechia
Site recruitment: Not reported
Facility not reported
Jihlava, Czechia
Site recruitment: Not reported
Facility not reported
Liberec, Czechia
Site recruitment: Not reported
Facility not reported
Mníšek pod Brdy, Czechia
Site recruitment: Not reported
Facility not reported
Olomouc, Czechia
Site recruitment: Not reported
Facility not reported
Pilsen, Czechia
Site recruitment: Not reported
Facility not reported
Prague, Czechia
Site recruitment: Not reported
Facility not reported
Ústí nad Labem, Czechia
Site recruitment: Not reported
Facility not reported
Zlín, Czechia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

ClinicalTrials.gov · NCT00170157 · Registry updated: 2017-05-15

Condition / research focus: Prostate Adenocarcinoma; Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage III Prostate Cancer; Stage IV Prostate Cancer
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2004-06. Completion: 2013-06 (may be estimated). Results are posted in this registry.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Bicalutamide (drug) — also listed as: Casodex, Cosudex, ICI 176,334, ICI 176334
Flutamide (drug) — also listed as: 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Chimax, Drogenil, Euflex, Eulexin, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolid, Oncosal, Profamid, Prostacur, Prostadirex, Prostica, Prostogenat, SCH 13521, Tafenil, Tecnoflut, Testotard
Goserelin Acetate (drug) — also listed as: ZDX, Zoladex
Ipilimumab (drug) — also listed as: Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy
Leuprolide Acetate (drug) — also listed as: A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur
Pharmacological Study (other)

Where the study takes place — 1 listed sites

Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer

ClinicalTrials.gov · NCT02212197 · Registry updated: 2017-04-25

Condition / research focus: Prostate Cancer
Sponsor: Camurus AB
Countries with listed sites: Finland · Hungary
Registry dates and results: Start: 2014-09. Completion: 2016-03 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

leuprolide acetate FluidCrystal® injection depot (drug) — also listed as: CAM2032
leuprolide acetate (drug) — also listed as: Eligard

Where the study takes place — 7 listed sites

Docrates Cancer Center
Helsinki, Finland
Site recruitment: Not reported
University Hospital of Helsinki, Department of Urology
Helsinki, Finland
Site recruitment: Not reported
Tampere University Hospital, Department of Urology
Tampere, Finland
Site recruitment: Not reported
University Hospital of Turku, Department of Urology
Turku, Finland
Site recruitment: Not reported
Semmelweis University Hospital Department of Urology
Budapest, Hungary
Site recruitment: Not reported
Szent Imre Teaching Hospital
Budapest, Hungary
Site recruitment: Not reported
University of Debrecen, Medical Health Sciences Center, Department of Urology
Debrecen, Hungary
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial

ClinicalTrials.gov · NCT00380406 · Registry updated: 2017-04-05

Condition / research focus: Fertility Preservation; Cancer
Sponsor: Ottawa Hospital Research Institute
Countries with listed sites: Canada
Registry dates and results: Start: 2007-01. Completion: 2010-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprolide acetate (drug)

Where the study takes place — 4 listed sites

Cancer Centre of Southeastern Ontario
Kingston, Ontario, Canada
Site recruitment: Not reported
Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, Canada
Site recruitment: Not reported
Kingston General Hospital
Ottawa, Ontario, Canada
Site recruitment: Not reported
Ottawa Hospital/OHRI
Ottawa, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"

ClinicalTrials.gov · NCT02167893 · Registry updated: 2017-03-29

Condition / research focus: Prostate Cancer
Sponsor: Takeda
Countries with listed sites: No country reported
Registry dates and results: Start: 2005-10. Completion: 2010-12 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprorelin acetate (drug) — also listed as: Leuplin SR 11.25 mg Injection Kit

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Relationship Between the Menstrual Cycle and Heart Disease in Women

ClinicalTrials.gov · NCT01546454 · Registry updated: 2017-03-22

Condition / research focus: Coronary Heart Disease
Sponsor: Oregon Health and Science University
Countries with listed sites: United States
Registry dates and results: Start: 2012-02. Completion: 2013-01 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ethinyl Estradiol-Levonorgestrel combination (drug) — also listed as: Portia 21, Portia 28
leuprolide acetate (drug) — also listed as: Eligard
Estradiol (drug) — also listed as: Vivelle-Dot
Progesterone (drug) — also listed as: First-Progesterone VGS

Where the study takes place — 1 listed sites

Oregon Health & Sciences University, Department of Obstetrics and Gynecology, Women's Health Research Unit
Portland, Oregon, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease

ClinicalTrials.gov · NCT01933022 · Registry updated: 2017-03-09

Condition / research focus: Metastatic Prostate Cancer
Sponsor: Astellas Pharma Europe Ltd.
Countries with listed sites: Netherlands
Registry dates and results: Start: 2014-08. Completion: 2015-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Eligard (drug) — also listed as: Leuprorelin acetate

Where the study takes place — 3 listed sites

Site NL31005 St. Antonius ziekenhuis
Nieuwegein, Netherlands
Site recruitment: Not reported
Site NL31004 Radboudumc
Nijmegen, Netherlands
Site recruitment: Not reported
Site NL31001 Canisius-Wilhelmina Ziekenhuis
Nijmegen, Netherlands
Site recruitment: Not reported

Original record, eligibility, contacts and results →